A forum on healthcare policy and professional issues, by Glasgow-based GP and FT Weekend columnist Margaret McCartney
From the category archives:
I can’t understand the blame being apportioned in press coverage over NICE’s decision not to fund Avastin, or bevacizumab, for the treatment of advanced bowel cancer. Many patients groups are laying the blame with NICE. Is this fair?
The important bit to me is ‘cost effectiveness’. It isn’t about either cost or effectiveness alone. While Roche [...]
{ 3 comments }
The latest on AstraZeneca, who are having to pay 198 million US dollars to patients who have developed diabetes on the anti psychotic drug quetiapine is only one bit of a long story. The challenge being made is that the weight gain and tendency to diabetes for some patients was known by AstraZeneca but not acknowledged fully on the [...]
{ 0 comments }
at least, I think so
{ 0 comments }
The Drugs and Therapeutics Bulletin is campaigning against Novartis’ decision to stop production of a particular type of insulin – one which has been around for years, is very reliable, and which is used by around 90,000 patients. Novartis say that the use of this insulin – Mixtard 30- is dropping: and that this type of insulin [...]
{ 0 comments }
I’m most impressed at the unabashed and vigorous plea for ’medical professionalism’ when it comes to doctors and their relationships with pharmaceutical and other commercial companies in the US. It’s in this report, just out, from the Association of American Medical Colleges. It places the need for clear information about potential financial and other biases in [...]
{ 0 comments }
Wonder drugs are rare. Applying the criteria of effectiveness, usefulness and cost, I’d put paracetamol, morphine and penicillin high on my list. The number one position, however, would go to aspirin. Not only is it good for pain relief, as an anti-inflammatory and to reduce fever, it also works as a blood-thinning agent, to decrease [...]
{ 0 comments }
My interviewee has asked for her surname and current place of work not to appear here.
Louise is the perfect science pin-up girl: blonde, slim, and dressed in denim and boots when I meet her on campus. She works as a university teacher, facilitating medical students in “problem based learning” sessions. I have arranged to meet [...]
{ 0 comments }
I may not have seen a pharmaceutical rep for over five years, but still the branded pens they gift to medics continue to infiltrate my house and my handbag. I conciously throw out the drug company pens I find, but they just seep back in: every time I lose my own plain biro, there is [...]
{ 4 comments }
Or perhaps not so much a makeover, but a radical shift in how drug research is decided upon, performed and reported. The suggestions come from Sir Iain Chalmers, who is editor of the James Lind Library in Oxford, and Silvio Garattini, director of the Mario Negri Institute for Pharmacological Research in Milan. Writing in the [...]
{ 0 comments }
I’ve been reading a brave book that I wanted to like but I don’t. It is called Drug Truths: Dispelling the Myths about Pharma R&D. The author is John L LaMattina, who is the retired president of Pfizer Global Research and Development.
The pharmaceutical industry has had a bad press over the past couple of years, [...]
{ 0 comments }
